Concepedia

Author

Anna Turletti

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

A Turletti, A. Turletti, Anna Turletti, Francesco Atzori, P. Tralongo

104

Publications

912

Citations

14

H-Index

17

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoOspedale MartiniIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Azienda Sanitaria Ospedaliera S.Croce e Carle CuneoUniversity of Turin
AT

About

Anna Turletti is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, breast cancer, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

609

2

Health Sciences

2

2

47

3

Pathology

2

2

235

4

Immunology

1

1

224

5

Pharmacology

1

1

11

Anna Turletti

×

15

Publications

843

Citations

13

H-Index

YearCitations

Tumor-Associated Transforming Growth Factor-β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients

Graziella Bellone, Anna Turletti, Elisa Artusio,

American Journal Of Pathology

1999

224

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Lucia Del Mastro, Sabino De Placido, Paolo Bruzzi,

The Lancet

2015

196

Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1

Graziella Bellone, S. Silvestri, Elisa Artusio,

Journal of Cellular Physiology

1997

69

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna,

The Breast

2019

52

Bone Marrow Stroma-Derived Prolactin Is Involved in Basal and Platelet-Activating Factor–Stimulated In Vitro Erythropoiesis

Graziella Bellone, Paola Astarita, Elisa Artusio,

Blood

1997

49

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Lucia Del Mastro, Francesca Poggio, Eva Blondeaux,

The Lancet Oncology

2022

46

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

Matteo Lambertini, Marcello Ceppi, Francesco Cognetti,

European Journal of Cancer

2016

44

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.

Pierfranco Conté, Giancarlo Bisagni, Antonio Frassoldati,

Journal of Clinical Oncology

2017

36

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Pierfranco Conté, Giancarlo Bisagni, Federico Piacentini,

Journal of Clinical Oncology

2023

24

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Marina Elena Cazzaniga, Mario Airoldi, Valentina Arcangeli,

The Breast

2017

23

Page 1